Headlines about Champions Oncology (NASDAQ:CSBR) have trended somewhat positive this week, according to Accern. The research group rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Champions Oncology earned a coverage optimism score of 0.04 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 47.1843741790499 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Shares of Champions Oncology (NASDAQ CSBR) traded up $0.09 during trading hours on Thursday, hitting $4.11. 8,400 shares of the stock traded hands, compared to its average volume of 34,250. The firm has a market cap of $44.17, a PE ratio of -9.79 and a beta of -0.48. Champions Oncology has a one year low of $2.19 and a one year high of $4.79.
Champions Oncology (NASDAQ:CSBR) last issued its earnings results on Thursday, December 7th. The biotechnology company reported ($0.01) EPS for the quarter. The firm had revenue of $5.20 million during the quarter. Champions Oncology had a negative net margin of 26.26% and a negative return on equity of 593.68%.
Separately, ValuEngine cut shares of Champions Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday, December 6th.
About Champions Oncology
Champions Oncology, Inc is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS segment provides physicians and patients information to help guide the development of personalized treatment plans.
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.